Blockbuster Sales, Lawsuits, and Approvals: Is There a Recovery in Sight for Bayer in 2026?

Why It Matters

The turnaround will determine Bayer’s ability to fund its R&D pipeline and offset legacy liabilities, influencing both the pharma and agro‑chemical markets.

Key Takeaways

• Bayer's Crop Science Q1 2026 sales hit $15.6 billion, EBITDA up 9%.
• Nubeqa and Kerendia boost pharma; Xarelto sales down 33% post‑patent.
• $7.25 billion Roundup settlement faces legal challenges, prolonging litigation risk.
• Asundexian gets FDA priority review, set to replace Xarelto.

Pulse Analysis

Bayer’s current predicament is rooted in the 2018 $63 billion Monsanto acquisition, which saddled the group with massive Roundup litigation. Hundreds of thousands of lawsuits allege the glyphosate‑based herbicide causes cancer, and a proposed $7.25 billion settlement has hit procedural roadblocks. Coupled with a 13,500‑person workforce reduction aimed at trimming $2.3 billion in costs by 2026, the company is aggressively reshaping its balance sheet while trying to preserve cash flow for core operations.

On the pharmaceutical side, Bayer shows a split picture. Its oncology and kidney‑disease drugs, Nubeqa and Kerendia, are delivering robust growth—Nubeqa’s net sales are projected at $2.7 billion and Kerendia’s revenue surged 88%, positioning both as emerging blockbusters. Conversely, legacy products Xarelto and Eylea have suffered steep declines after patent cliffs opened the market to generics and biosimilars, dragging overall pharma revenue down 3.7%. The pipeline offers a potential lift: asundexian, a Factor XIa inhibitor, earned FDA priority review and could recapture anticoagulant market share, while Lynkuet targets a niche menopause market with an estimated $1.16 billion peak sales.

Looking ahead, Bayer’s strategy hinges on leveraging its strong Crop Science cash generation—Q1 EBITDA rose 9% to $5.19 billion—to fund R&D and navigate legal exposure. If asundexian clears regulatory hurdles, it may offset the Xarelto revenue gap and restore investor confidence. However, lingering litigation and the need for continued cost discipline mean the company’s recovery remains contingent on disciplined execution across both its agro‑chemical and pharmaceutical divisions.